Asymptomatic versus symptomatic SARS-CoV-2 infection: a cross-sectional seroprevalence study

El-Ghitany, Engy Mohamed; Hashish, Mona H.; Farghaly, Azza Galal; Omran, Eman A.; Osman, Nermin A.; Fekry, Marwa M.

doi:10.1186/s41182-022-00490-9

Tropical Medicine and Health

Table 4 Correlation matrix between some quantitative factors among the studied participants

From: Asymptomatic versus symptomatic SARS-CoV-2 infection: a cross-sectional seroprevalence study

		1	2	3	4	5	6	7	8	9	10	11
Spearman’s rho
1	R	1.000	0.108**	0.030	0.186*	− 0.317**	0.061*	− 0.004	0.174**	− 0.017	0.106	− 0.161**
1	P	NA	< 0.001	0.714	0.023	< 0.001	0.022	0.949	< 0.001	0.561	0.172	< 0.001
2	r	0.108**	1.000	0.006	0.200*	− 0.250**	0.039	0.038	0.062	− 0.047	0.093	− 0.126**
2	p	< 0.001	NA	0.949	0.019	0.003	0.159	0.531	0.054	0.122	0.259	0.005
3	r	0.030	0.006	1.000	0.052	0.064	− 0.023	NA	− 0.032	− 0.016	NA	0.095
3	p	0.714	0.949	NA	0.528	0.441	0.785	NA	0.712	0.850	NA	0.374
4	r	0.186*	0.200*	0.052	1.000	0.127	0.240**	0.730	− 0.024	− 0.047	0.000	− 0.018
4	p	0.023	0.019	0.528	NA	0.124	0.003	0.099	0.782	0.566	1.000	0.869
5	r	− 0.317**	− 0.250**	0.064	0.127	1.000	− 0.089	− 0.483	− 0.014	0.007	0.032	0.041
5	p	< 0.001	0.003	0.441	0.124	NA	0.278	0.331	0.874	0.936	0.925	0.701
6	r	0.061*	0.039	− 0.023	0.240**	− 0.089	1.000	− 0.154**	− 0.295**	− 0.303**	0.418**	− 0.101*
6	p	0.022	0.159	0.785	0.003	0.278	NA	0.007	< 0.001	< 0.001	< 0.001	0.018
7	r	− 0.004	0.038	NA	0.730	− 0.483	− 0.154**	1.000	NA	− 0.100	NA	− 0.212
7	p	0.949	0.531	NA	0.099	0.331	0.007	NA	NA	0.082	NA	0.383
8	r	0.174**	0.062	− 0.032	− 0.024	− 0.014	− 0.295**	NA	1.000	− 0.080*	− 0.025	− 0.252**
8	p	< 0.001	0.054	0.712	0.782	0.874	< 0.001	NA	NA	0.019	0.757	< 0.001
9	r	− 0.017	− 0.047	− 0.016	− 0.047	0.007	− 0.303**	− 0.100	− 0.080*	1.000	0.100	0.052
9	p	0.561	0.122	0.850	0.566	0.936	< 0.001	0.082	0.019	NA	0.211	0.222
10	r	0.106	0.093	NA	0.000	0.032	0.418**	NA	− 0.025	0.100	1.000	− 0.141
10	p	0.172	0.259	NA	1.000	0.925	< 0.001	NA	0.757	0.211	NA	0.113
11	r	− 0.161**	− 0.126**	0.095	− 0.018	0.041	− 0.101*	− 0.212	− 0.252**	0.052	− 0.141	1.000
11	p	< 0.001	0.005	0.374	0.869	0.701	0.018	0.383	< 0.001	0.222	0.113	. NA

NA: not analyzed
1-Number of symptoms
2-Anti-S titer
3-Frequency of COVID-19 diagnosed infections
4-Duration after which patient improved (days)
5-Duration since SARS-CoV-2 infection (months)
6-Age (years)
7-WHO CHILD BMI
8- WHO ADULT BMI
9-Crowding index
10-Smoking index
11-Number of online working days

Back to article page

ISSN: 1349-4147

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com